Hydroxyzine

Lore & Background

Hydroxyzine works by blocking the effects of histamine as a potent and selective histamine H1 receptor inverse agonist. It also acts more weakly as an antagonist of serotonin 5-HT2A, dopamine D2, and α1-adrenergic receptors, which likely underlies its usefulness as an anxiolytic. A positron emission tomography study found that a single 30 mg dose occupied 67.6% of brain H1 receptors, with subjective sleepiness correlating with that occupancy. The drug crosses the blood–brain barrier easily and is metabolized in the liver, with its main metabolite cetirizine formed primarily through the action of alcohol dehydrogenase and aldehyde dehydrogenase.

Reader's Guide

Hydroxyzine's significance lies in its broad clinical utility as a first-generation antihistamine with anxiolytic and sedative properties. A systematic review concluded it outperforms placebo for generalized anxiety disorder, though insufficient data exist to compare it with benzodiazepines or buspirone. Common side effects include sleepiness, headache, and dry mouth; serious side effects may include QT prolongation. It is contraindicated during pregnancy based on animal studies showing fetal abnormalities at high doses, and its use in older adults is cautioned due to potential severe side effects.

Did You Know?

• A systematic review found hydroxyzine outperforms placebo for generalized anxiety disorder, but insufficient data exist to compare it with benzodiazepines or buspirone.
• Hydroxyzine's main metabolite, cetirizine, is formed primarily through the action of alcohol dehydrogenase and aldehyde dehydrogenase.

Therapeutic Reach and Clinical Evidence

Hydroxyzine occupies a remarkably broad therapeutic niche for a single compound. Marketed under names like Atarax and Vistaril, this antihistamine is deployed against conditions ranging from persistent skin itching and histamine-driven allergic reactions—chronic urticaria, atopic dermatitis, contact dermatoses—to generalized anxiety, motion-sickness nausea, and difficulty falling asleep. It can be swallowed or delivered via intramuscular injection, giving clinicians flexibility in administration. The evidence base is mixed but notable. A systematic review found hydroxyzine to be superior to placebo for generalized anxiety disorder, though researchers acknowledged insufficient data to compare it head-to-head with benzodiazepines or buspirone. For insomnia, a 2022 network meta-analysis found scant supporting evidence, while a 2023 meta-review offered a more nuanced view: the drug helps patients fall asleep faster but is less effective at sustaining sleep through a full night. Because tolerance to its sedating effects can emerge within days, prescribers typically limit it to short-term or as-needed use, with sleep doses between 25 and 100 milligrams. In the perioperative setting, hydroxyzine does not interfere with tropane alkaloids like atropine but can potentiate meperidine and barbiturates after general anesthesia, necessitating careful dose adjustment.

Safety Landscape and Contraindications

The safety profile of hydroxyzine carries both everyday inconveniences and genuinely serious risks. The most frequently reported effects—drowsiness, headache, and dry mouth—reflect its mild antimuscarinic properties, which also explain occasional constipation. More concerning are episodes of hypotension, tinnitus, incoordination, and, in rare overdosing cases, hallucinations or confusion. The drug can prolong the QT interval, a cardiac effect that warrants monitoring. Contraindications are specific and non-negotiable. Subcutaneous and intra-articular injection are prohibited. The FDA has issued guidelines against use during early pregnancy, after animal studies in rats, mice, and rabbits revealed fetal abnormalities—including hypogonadism—at doses well above the human therapeutic range. Combining hydroxyzine with other central nervous system depressants is contraindicated unless doses are kept minimal, and patients on any regimen should avoid operating machinery or driving. Perhaps most striking is the tardive dyskinesia risk. While typically associated with years of continuous use, cases of involuntary head rolling, lip-licking, and athetoid movements have been reported after as few as seven and a half months. Elderly patients with prior phenothiazine exposure face heightened vulnerability, and the drug now appears on lists of medications to avoid in older adults.

Pharmacological Identity and Mechanism

Chemically, hydroxyzine sits within the piperazine family and is categorized as a first-generation antihistamine. Its primary pharmacodynamic action is the blockade of histamine receptors, explaining its effectiveness against allergic itching, urticaria, and other histamine-mediated conditions. Beyond that core mechanism, the drug exerts a broader calming influence on the central nervous system, with observations suggesting it stimulates regions within the reticular formation to produce an overall sedative and anxiolytic effect rather than a narrowly targeted one. This broader CNS suppression explains several behavioral signatures. Patients often report intense subjective sedation upon first taking the drug, yet that sensation fades markedly over five to seven days as receptors desensitize. It functions as an acute hypnotic, shortening sleep-onset latency and modestly extending total sleep duration, with female patients showing a stronger hypnotic response. The mild antimuscarinic activity contributes to the dry mouth and constipation that accompany use. Notably, hallucinogenic or deeply hypnotic effects occasionally attributed to hydroxyzine in clinical anecdotes have not been consistently reproduced in controlled trials when the drug is taken alone. Those dramatic presentations tend to emerge when hydroxyzine is layered on other CNS-active agents such as lithium or ethanol, suggesting the more extreme effects are additive rather than intrinsic.

From Belgian Laboratory to Mainstream Prescription

Hydroxyzine's journey from laboratory to pharmacy shelf began in 1956, when the Belgian company Union Chimique Belge first synthesized the compound. Within the same year, Pfizer secured approval to market it in the United States, and it entered clinical circulation under brand names that would become familiar in dermatology and psychiatry—Atarax and Vistaril, among others. Nearly seven decades later, the molecule's footprint in American medicine is substantial. In 2023, hydroxyzine ranked as the thirty-ninth most commonly prescribed medication in the United States, accumulating more than fifteen million prescriptions in a single year. That volume underscores how far the drug has traveled from its original role as a simple antihistamine for itching to a multi-purpose agent touching anxiety, sleep, and nausea management across diverse patient populations. Yet even with that ubiquity, important questions remain unresolved. The safety of hydroxyzine during pregnancy and breastfeeding has not been definitively established, and the FDA's cautionary stance reflects the absence of a clearly defined safe dose in those populations. The gap between its widespread everyday use and the lingering uncertainty around vulnerable patient groups remains one of the drug's most significant open threads.

Gallery